Phaseline

Companies › NX Development

NX Development: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Gleolan
Prodrug metabolized to Protoporphyrin IX (PpIX) for fluorescence-guided visualization of t
–Phase 3Ovarian CancerSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05804370GleolanPhase 3Ovarian CancerOncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.